Literature DB >> 3289935

Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors.

F Calais da Silva1, L Denis, A Bono, C Bollack, C Bouffioux.   

Abstract

The authors report the preliminary data concerning a multicentric study on ablative effects of 4'-epi-doxorubicin (EPR) on superficial bladder cancer. Forty-six patients affected by multiple transitional cell superficial bladder carcinoma were treated by transurethral resection of all but one tumor, left as a marker lesion. Subsequently, an intensive local treatment with EPR and 3-month control cystoscopies with biopsies were performed. In the 47% of cases the control cystoscopy and pathology assessed the complete disappearance of marker lesions without any new occurrence whereas it is interesting to observe that the breakdown of the complete remissions into primary (67%) versus recurrent (37%) and in intravesical unpretreated (55%) versus pretreated (31%) showed important differences. It may be concluded that EPR shows a real activity against transitional cell superficial bladder carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289935     DOI: 10.1159/000472938

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

Review 1.  [Early instillation in superficial bladder carcinoma. Current status].

Authors:  S Langbein; A Häcker; J K Badawi; M S Michel; P Alken
Journal:  Urologe A       Date:  2004-12       Impact factor: 0.639

Review 2.  Superficial bladder cancer: state of the art.

Authors:  A V Bono
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.

Authors:  H Eto; Y Oka; K Ueno; I Nakamura; K Yoshimura; S Arakawa; S Kamidono; S Obe; T Ogawa; G Hamami
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.

Authors:  A P van der Meijden; K H Kurth; W Oosterlinck; F M Debruyne
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Epirubicin: a review of its intravesical use in superficial bladder cancer.

Authors:  S V Onrust; L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 4.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.